Tecovirimat SIGA – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Tecovirimat SIGA, as authorised in the European Union and published in the Union Register of medicinal products.
Before anything else
ℹ️ 1. What Tecovirimat SIGA is and what it is used for
Tecovirimat SIGA contain s the active ingredient tecovirimat.
Tecovirimat SIGA is used to treat viral infections, such as smallpox and cowpox in adults and children weighing at least 13 kg.
Tecovirimat SIGA is also used to treat complications from smallpox vaccines.
Tecovirimat SIGA works by stopping the virus from spreading. This will help your own body to build up protection against the virus until you are better.
⚠️ 2. What you need to know before you take Tecovirimat SIGA
Do not take Tecovirimat SIGA
- if you are allergic to T ecovirimat SIGA or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking T ecovirimat SIGA .
- if your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high -dose corticost eroids, immunosuppres ants or cancer medicines).
- If you have reduced function of your liver or kidneys.
27 Children weighing less than 13 kg This medicine should not be given to children who weigh less than 13 kg.
Other medicines and Tecovirimat SIGA
Tell your doctor if you are taking, have recently taken or might take any other medicines.
You must tell your doctor if you are taking any of the following medicines :
- repaglinide (a medicine used to treat blood sugar levels in diabetes)
- omeprazole, lansoprazole, or rabeprazole (used to treat ulcers or heart burn)
- midazolam (a medicine used to put people to sleep before a surgical procedure)
- bupropion (a medicine used to treat depression)
- atorvastatin (a medicine use to treat high cholesterol)
- flurbiprofen (a medicine used to treat pain)
- calcium acetate, lanthanum carbonate, sevelamer carbonate, or sucroferric oxyhydroxide (used to reduce high blood phosphate levels)
- methadone (a medicine used to treat pain or withdrawal symtoms of narcotics)
- darunavir , maraviroc, or rilpivirine (used to treat HIV infection)
- sildenafil, tadalafil, or vardenafil (used to treat erectile dysfunction)
- voriconazole (a medicine used to treat fungus infections)
- tacrolimus (a medicine used to suppress the immune system Taking Tecovirimat SIGA with any of these may stop your medicines from working properly, or make any side effects worse. Your doctor may need to give you a different medicine or adjust the dose of medicine you are taking. The above is not a complete list of medicines that your doctor may need to alter.
Pregnancy and breast -feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Tecovirimat SIGA is not recommended during pregnancy.
It is not known whether Tecovirmat SIGA is excreted in human milk. Breast -feeding is not recommen ded during treatment with this medicine. Tell your doctor if you are breast -feeding or are planning to breast -feed before taking this medicine.
Driving and using machines
Do not drive or operate machines if you feel dizzy.
Tecovirimat SIGA cont ains Lactose and sunset yellow (E110)
- Tecovirimat SIGA contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
- This medicine also contains sunset yellow (E110), a colouring agent. This may cause allergic reactions.
💊 3. How to take Tecovirimat SIGA
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Adults and children weighing at least 13 kg 28 The recommended dose s are described in the table below.
Body Weight Dose 13 kg to less than 25 kg One Tecovirimat SIGA 200 mg capsule every 12 hours for 14 days (200 mg two times a day) 25 kg to less than 40 kg Two Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days (400 mg two times a day) 40 kg to less than 120 kg Three Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days (600 mg two times a day) 120 kg and above Three Tecovirimat SIGA 200 mg capsules every 8 hours for 14 days (600 mg three times a day) Method of a dministration Take Tecovirimat SIGA within 30 minutes after eating a full meal of at least 600 calories. The meal should contain at least 25 grams of fat . This can be achieved with many common foods (e.g., 2 big handfuls of nuts, 2 tablespoon s of oil , or 1.5 tablespoons of butter ). This is very important to ensure that a sufficient amount of the medicine is taken up by your body. Swallow the capsules whole with 150ml to 200ml of water.
Adults and children who have difficulty swallowing capsules For patients who are not able to swallow the capsules, the doctor may recommend opening the hard capsule and mixing the contents with 30 mL of liquid (e.g., milk, chocolate milk) or soft food (e.g., apple sauce, yogurt).
Wash and dry your hands before and after preparation. Carefully o pen the capsule so that the contents do not spill or escape into the air. Hold the capsule with the cap facing up and pull the cap away from the body of the capsule. Use a small container for mixing. Mix the entire contents of the capsule with 30 mL of liquid (e.g. milk) or soft food (e.g. yogurt) . The mixture should be taken within 30 minutes after mixing and within 30 minutes of eating a meal .
The recommended paediatric and a dult dosage and p reparation instructions are given in the table below.
Body weight Tecovirimat dose Amount of liquid or soft food Number of capsules Food and tecovirimat mixture instructions 13 kg to less than 25 kg 200 mg 2 tablespoons 1 Tecovirimat capsule Mix entire contents of 1 Tecovirimat capsule with 2 tablespoons of liquid or soft food.
25 kg to less than 40 kg 400 mg 2 tablespoons 2 Tecovirimat capsules Mix entire contents of 2 Tecovirimat capsules with 2 tablespoons of liquid or soft food.
40 kg to less than 120 kg 600 mg 2 tablespoons 3 Tecovirimat capsules Mix entire contents of 3 Tecovirimat capsules with 2 tablespoons of liquid or soft food.
120 kg and above 600 mg 2 tablespoons 3 Tecovirimat capsules Mix entire contents of 3 Tecovirimat capsules with 2 tablespoons of liquid or soft food.
If you take more Tecovirimat SIGA than you should
Let your doctor know if you take too many Tecovirimat SIGA capsules so that your doctor can monitor you for any signs or symptoms of side effects.
29 If you forget to take Tecovirimat SIGA If you miss a dose, skip that dose and continue with your next schedule d dose. Do not take a double dose to make up for a forgotten dose.
If you stop taking Tecovirimat SIGA, your symptoms may return or become worse
Do not stop taking Tecovirimat SIGA before you have completed the course, or without talking to your doctor or pharmacist first.
If you vomit after taking Tecovirimat SIGA If you vomit within 30 minutes of taking Tecovirimat SIGA, you may take another dose right away.
If you vomit more than 30 minutes after taking Tecovirimat SIGA, do not take another dose and continue with your next scheduled dose .
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
❗ 4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Very common side effects (may affect more than 1 in 10 people)
- Headache
Common side effects (may affect up to 1 in 10 people)
- Dizziness
- Feeling sick (nausea) or vomiting
- Diarrhoea
- Abdominal pain
Uncommon side effects (may affect up to 1 in 100 people)
- Decreased appetite
- Increased liver enzymes
- Depression or anxiety
- Irritability
- Depression
- Panic attacks
- Migraine
- Feeling tired or sleepy or unable to sleep
- Being unable to concentrate or having a low attention span
- Taste disturbances
- Tingling or numbness in the hands, feet or or mouth
- Mouth pain
- Constipation
- Flatulence
- Indigestion or upset stomach
- Abdominal discomfort or swelling
- Dry mouth
- Dry or chapped lips
- Mouth ulcers
- Belching or burping 30 • Heartburn
- Itching or rash (hives)
- Joint pain and stiffness
- Fever
- Chills
- Generally feeling unwell (malaise)
- Pain
- Feeling thirsty
- If you have a scan of your brain’s electrical activity called an electrocephalogram, it may show abnormal readings of electrical activity of the brain.
- If you have a blood test, it may show that you have lower numbers of red blood cells or white blood cells or platelets than usual.
- Increased heart rate (tachycardia) or irregular heart rate
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects , you can help provide more information on the safety of this medicine.
🌡️ 5. H ow to store Tecovirimat SIGA
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month.
Store in the original package in order to protect from light.
Store below 25°C.
Do not use this medicine if you notice that the capsule is broken or damaged in any way.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
📦 6. Contents of the pack and other information
What Tecovirimat SIGA contains
- The active substance is tecovirimat monohydrate equivalent to 200 mg tecovirimat
- The other ingredients are:
Capsule core: Silica colloidal anhydrous , croscarmellose sodium (E468) , hypromellose (E464) , lactose monohydrate, magnesium stearate, cellulose, microcrystalline (E 460) and sodium laurils ulfate (E487) .
Capsule shell : gelatin, brilliant blue FCF (E133), erythrosine (E127), sunset yellow (E110) and titanium dioxide (E171).
Printing ink : shellac (E904), titanium dioxide (E171), isopropyl alcohol, ammonium hydroxide (E527), butyl alcohol, propylene glycol, and simeticone.
31 What Tecovirimat SIGA looks like and contents of the pack
- Tecovirimat SIGA are orange and black capsules, each printed with ‘SIGA®’ and ‘ST -246’ in white ink. The capsules are 21.7 millimeters long and 7.64 millimeters in diameter .
- Tecovirimat SIGA is available in a pack containing 84 ( 2 bottles of 42) capsules.
Marketing Authorisation Holder
SIGA Technologies Netherlands B.V.
Prinsenhil 29, Breda 4825 AX, The Netherlands
Manufacturer
Millmount Healthcare Limited Block -7, City North Business Campus, Stamullen Co. Meath K32 YD60 Ireland
This leaflet was last revised i n
This medicine has been authorised under ‘e xceptional circumstances’. This means that for ethical reasons it has been impossible to get complete information on this medicine.
The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
📄 Package Leaflet – official source
This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Tecovirimat SIGA (PDF, ec.europa.eu).
You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/21/1600).
⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.